Evidence map›Paper›PMID 40922427›Full record

ArticleJournal of gastroenterology and hepatology2025

Liver Stiffness Measurements After Oral Antivirals Effectively Predict the Risk of HCC in Patients With Chronic Hepatitis C.

Yu Rim Lee, Hyun Young Woo, Young Oh Kweon, Won Young Tak, Se Young Jang, Jung Gil Park, Min Kyu Kang, Jeong Eun Song, Byoung Kuk Jang, Changhyeong Lee and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gastroenterology and hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Yu Rim LeeDepartment of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, South Korea.ORCID https://orcid.org/0000-0003-1916-1448
Hyun Young WooDepartment of Internal Medicine, College of Medicine, Pusan National University and Medical Research Institute, Pusan National University Hospital, Busan, South Korea.
Young Oh KweonDepartment of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, South Korea.
Won Young TakDepartment of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, South Korea.ORCID https://orcid.org/0000-0002-1914-5141
Se Young JangDepartment of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, South Korea.
Jung Gil ParkDepartment of Internal Medicine, Yeungnam University College of Medicine, Daegu, South Korea.
Min Kyu KangDepartment of Internal Medicine, Yeungnam University College of Medicine, Daegu, South Korea.ORCID https://orcid.org/0000-0002-1435-3312
Jeong Eun SongDepartment of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, South Korea.ORCID https://orcid.org/0000-0002-1034-4478
Byoung Kuk JangDepartment of Internal Medicine, Keimyung University School of Medicine, Daegu, South Korea.
Changhyeong LeeDepartment of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, South Korea.
Byung Seok KimDepartment of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, South Korea.
Jae Seok HwangDepartment of Internal Medicine, Keimyung University School of Medicine, Daegu, South Korea.
Woo Jin ChungDepartment of Internal Medicine, Keimyung University School of Medicine, Daegu, South Korea.
Jeong HeoDepartment of Internal Medicine, College of Medicine, Pusan National University and Medical Research Institute, Pusan National University Hospital, Busan, South Korea.
Nae-Yun HeoDepartment of Internal Medicine, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, South Korea.ORCID https://orcid.org/0000-0001-6571-8935
Seung Ha ParkDepartment of Internal Medicine, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, South Korea.ORCID https://orcid.org/0000-0002-5950-2713
Jun Sik YoonDepartment of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea.
Joonho JeongDepartment of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, South Korea.
Sang Gyu KwakDepartment of Medical Statistics, Daegu Catholic University School of Medicine, Daegu, South Korea.
Yeowool KangDepartment of Internal Medicine, Dong-A University Hospital, Busan, South Korea.
Yang Hyun BaekDepartment of Internal Medicine, Dong-A University Hospital, Busan, South Korea.
Soo Young ParkDepartment of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, South Korea.ORCID https://orcid.org/0000-0002-4944-4396

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveHepatocellular carcinoma (HCC) can still occur in patients with chronic hepatitis C after achieving a sustained virologic response (SVR) with direct-acting antiviral (DAA) therapy. Therefore, we aimed to identify and validate predictors and HCC risk models using longitudinal data.

methodThis retrospective cohort study included patients who achieved SVR after DAA therapy. Model performance was assessed using Harrell's C-index and the area under the time-dependent receiver operating characteristic curve (AUROC).

resultsAfter excluding patients who developed HCC or died within 1 year after achieving SVR, a total of 2778 patients were finally included in this study. 154 (5.5%) patients developed HCC at a median of 3.3 years. LSM value showed significant improvement after antiviral therapy (all p < 0.05). In the multivariable analysis, LSM at baseline and 1 year after SVR were significantly associated with the occurrence of HCC (all p < 0.05). LSM at 1 year after SVR could better predict HCC risk than baseline LSM (C-index: 0.760, 0.788 at baseline, 1 year after SVR, respectively). Low-risk patients (LSM < 10 kPa) using LSM values at 1 year after SVR (76.4%) showed an incidence risk of 0.482 incidence rate/100 patient-years. In patients with advanced chronic liver disease, LSM at 1 year after SVR demonstrated superior predictive performance for HCC development compared to baseline LSM and other prediction models assessed at various time points (C-index: 0.744, 95% CI: 0.660-0.829; 3-year follow-up AUROC: 0.794, 95% CI: 0.754-0.831).

conclusionsLSM after achieving SVR effectively predicts HCC risk, especially in patients with advanced chronic liver disease.

Indexed as

Antiviral AgentsCarcinoma, HepatocellularElasticity Imaging TechniquesHepatitis C, ChronicLiverLiver NeoplasmsAdministration, OralAdultAgedCohort StudiesFemaleHumansMaleMiddle AgedPredictive Value of TestsRetrospective StudiesAntiviral Agentshepatitis C virushepatocellular carcinomaliver stiffnessrisk scoresustained virological response (SVR)

Identifiers

PMID40922427
PMCPMC12511839

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.